Ligand Pharmaceuticals (LGND), GSK's (GSK) promacta approved - Report
Ligand Pharmaceuticals (NASDAQ: LGND), GSK's (NYSE: GSK) promacta approved for treatment of low blood platelet counts in HepC patients, Adam Feuerstein reports.
You May Also Be Interested In
- Nektar Therapeutics (NKTR) Wins FDA Approval of Movanik
- UPDATE: Rackspace (RAX) Active on Chatter
- Micron Technology (MU) Trades Near Session Highs with Firm Volume
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!